This study was designed to determine the role of cholecystokinin in the control gastric acid secretion in men using loxiglumide, a specific cholecystokinin receptor blocker. Three groups of healthy subjects (A, B, and C) were used; group A -for studies with postprandial gastric secretion, group B -for studies with exogenous gastric secretagogues and group Cfor 12 hour intragastric pH-metry. Cephalic phase stimulated by modified sham feeding in group A subjects increased gastric acid secretion to about 50% of pentagastrin maximum and the treatment with loxiglumide in a standard dose (20 [tmolIkg iv loading dose plus infusion of 20 iumol/kg/h afterwards) failed to affect this secretion. Gastric acid response to a 5% peptone meal instilled intragastrically greatly enhanced gastric acid secretion and plasma gastrin concentration but the addition of loxiglumide in the standard dose resulted in further increase in both gastric acid and plasma gastrin responses to peptone meal. Infusion of caerulein in gradually increasing doses (15-120 pmollkg/h) and gastrin releasing peptide pmol/kg/h) resulted in a dose dependent stimulation of gastric acid secretion reaching about 35% and 25% of maximum attained with pentagastrin. When loxiglumide was added in a standard dose, the acid responses to caerulein and gastrin releasing peptide were further increased two to three fold attaining the peak reaching, respectively, about 100% and 50% ofpentagastrin maximum. In group C subjects, 12 hour pH-metry revealed the usual increase in gastric pH after each meal in tests with placebo. Loxiglumide (1200 mg tablets tid, po) resulted in significantly lower pH after each meal and this was accompanied by significantly higher gastrin responses than in placebo tests. We conclude that cholecystokinin released by peptone meal, ordinary meals or gastrin releasing peptide exerts a potent inhibitory influence on gastric acid secretion and gastrin release in men and this inhibition involves subtype A cholecystokinin receptors. (Gut 1993; 34: 321-328) Gastric acid secretion depends upon the interplay of many stimulatory and inhibitory influences that arise within the central nervous system and the gastrointestinal tract resulting in the cephalic, gastric, and intestinal phases of this secretion.'
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(Gut 1993; 34: 321-328) Gastric acid secretion depends upon the interplay of many stimulatory and inhibitory influences that arise within the central nervous system and the gastrointestinal tract resulting in the cephalic, gastric, and intestinal phases of this secretion. ' Cholecystokinin is one of major gut hormones2 that has also been implicated in the control of gastric secretion. Exogenous cholecystokinin or its natural analogue, caerulein, administered alone in fasted humans or in dogs`caused partial stimulation of gastric acid secretion but when combined with gastrin it inhibited gastrin induced secretion. The inhibitory action of cholecystokinin could not be, however, confirmed on the isolated canine parietal cells which respond to gastrin and cholecystokinin with equal stimulation of acid production.6 This discrepancy between the in vivo inhibition and in vitro stimulation by cholecystokinin of passed under fluoroscopic control for the aspira tion of gastric juice as described previously. Residual gastric contents were discarded and th gastric aspirates were collected by a suctio pump in 15 minute periods. After 45 minute basal period, the subjects were served an appetis ing meal of 250 g beef steak, 150 g frenc potatoes, with about 250 ml water to drink th food was tested, chewed and spat out for 1 minutes. The aspiration of gastric juice wa carried out during modified sham feeding an during consecutive 105 minute period. The pentagastrin (2 nmol/kg/h) was infused for 6 minutes and the aspiration of gastric juice wa continued to determine maximal acid output i these subjects. All meals were prepared in separate room so that subjects could not see smell the food until the time of modified shar feeding and each subject was trained in a prn liminary study not (Fig 2) . Loxiglumide added to iv infusion T resulted in a significant augmentation of acid response to peptone meal and this increase averaged about 30% of the control value obtained *4ba with peptone meal alone. Plasma gastrin rose from basal value of about 25 pmol/l to the plateau of about 80 pmol/l after peptone meal and this was further significantly increased when loxiglumide was added to iv infusion.
Caerulein infused iv in gradually increasing doses ranging from 15 to 120 pmol/kg/h resulted in a small but significant stimulation of gastric acid secretion reaching peak at a dose of 30 pmol/ kg/h and amounting to about 35% of pentagastrin induced maximal acid outputs in these subjects (Fig 3) . At a dose of 60 and 120 pmol/kg/h, acid outputs tended to decline but remained significantly higher than basal acid secretion. When infusion of caerulein was combined with a constant background dose of loxiglumide, gastric 200 (Fig 8) . Plasma gastrin levels between meals in placebo-treated subjects were similar to those in loxiglumide treated subjects but the postprandial increments in plasma gastrin with loxiglumide were significantly higher than in placebo controls (Table) .
Discussion
This study provides evidence that cholecystokinin exerts a tonic inhibitory action on gastric acid secretion and gastrin release in response to ordinary meals, gastric peptone or gastrin releasing peptide in man and that these effects are mediated by the type A cholecystokinin receptors. 18 20 Cephalic phase of gastric secretion elicited in the present study by modified sham feeding is assumed to be mediated by vagal nerves stimulatnel) and ing directly the oxyntic cells and activating the release of gastrin and histamine.'6 The reports concerning the rise in plasma gastrin after modified sham feeding in man are controversial, agastrin alone, confirmed by some investigators'7" and quesa that to penta-tioned by others.'3'9 The present study shows le in the same only a small and insignificant increment in plasma hormone concentration after the was added to modified sham feeding. The release of cholentagastrin at a cystokinin was observed only in anaesthetised bmaximal acid dogs with electrically stimulated vagal nerves20 n acid response but usual cephalic stimulation in conscious dogs ras completely attained by sham feeding or insulin hypocaerulein was glycaemia failed to result in any significant change in plasma cholecystokinin concentraistrin releasing tions.2' Our results in man show that the pretreatfusion of this ment with loxiglumide did not affect significantly doses (25- of gastric acid secretion reaching about 50% of pentagastrin maximum in these subjects. It was accompanied by several fold increase in plasma gastrin concentrations probably reflecting an excessive release of antral hormone as a result of gastric distention by the meal and the action of peptic digests at high pH on the antral G-cells. 4 The question remains whether such artificial gastrointestinal meal composed ofprotein digests stimulates the release of cholecystokinin in man and whether the amounts of hormone released are sufficient to affect gastric acid secretion. In our previous study with a similar gastric peptone meal in man, plasma cholecystokinin rose several fold over basal value and exogenous cholecystokinin in a dose as low as 20 pmol/kg/h caused significant inhibition of gastric acid secretion in response to this meal. As the pretreatment with loxiglumide completely abolished the inhibitory effect of exogenous cholecystokinin on meal induced gastric acid secretion we assumed that cholecystokinin induced gastric acid secretion was mediated by type A cholecystokinin receptors. The gastric acid secretion induced by peptone meal itself, however, was not affected by the loxiglumide in that study probably because of 20 the relatively low dose of loxiglumide (800 mg po plus iv infusion of 1 mg/kg/h) used. 20 [tmol/kg/h infused concen-iv afterwards) because our dog experiments does not revealed that the bioavailability of loxiglumide gastric from the gastrointestinal tract was only about 40%23 and because other reports showed that id secre-higher doses of this blocker in humans are safe he intra-and well tolerated.2429 Such large dose of loxikept at a glumide applied iv did not influence basal gastric ragastric acid secretion or basal plasma gastrin concentraure pre-tion (see Figure 6 ) but greatly augmented the H aftera peptone stimulated gastric acid secretion and rnulation significantly raised the postprandial plasma gastrin concentrations indicating that, indeed, cholecystokinin released by this peptone has a tonic inhibitory influence on both gastric acid secretion and gastrin release in man.
Peptone solution applied intragastrically is, however, highly artificial meal because it involves the constant neutralisation of secreted acid by intragastric titration and prevents the usual rise in the intragastric acidity after the meal. Therefore, we also used the most physiological assessment of intragastric acidity by continuous pH-metry using intraluminal pH electrode that has been recently validated in _ healthy subjects and peptic ulcer patients'"2 and used to monitor the action of various drugs on gastric acid secretion.2 Loxiglumide given orally three times daily before each meal did not influence the interdigestive pH but resulted in a ;upper significantly lower intragastric pH after each Do-20.00 meal indicating an overall increase in the postliapH in prandial gastric acid secretion. Yet, despite the indicates enhanced gastric acid secretion and lower intragastric pH, the plasma gastrin response to the Plasma gastrin concentrations as determined 60 and 30 minutes before each meal and 30, 60, and 90 minutes after each meal (breakfast, lunch, and supper) during 12 hour pH-metry tests in placebo and loxiglumide treated subjects. Means 
